The influence of age and sex on the clearance of cytochrome P450 3A substrates

被引:222
|
作者
Cotreau, MM
von Moltke, LL
Greenblatt, DJ
机构
[1] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
[2] Wyeth Ayerst Res, Expt Med, Cambridge, MA USA
关键词
D O I
10.2165/00003088-200544010-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450s (CYPs) are an important family of enzymes in the metabolism of many therapeutic agents and endogenous metabolic reactions. The CYP3A subfamily is especially prominent in these metabolic activities. This review article focuses on how the factors of age and sex may influence the in vivo activity of human CYP3A. The functional activity of CYP3A varies based on issues such as interaction with one or more substrates and between individuals and/or localisation. For CYP3A substrates, intrinsic clearance is the component of total clearance that is contributed by the enzymes. Depending on the route of administration and the contribution of hepatic blood flow to overall clearance, sensitivities to changes in CYP3A activities may differ. Additionally, age may influence the hepatic blood flow and, in turn, affect CYP3A activity. A review of the literature regarding age influences on the clearance of CYP3A substrates does suggest that age can affect the clearance of certain CYP3A substrates. CYP3A is responsible for a large number of endogenous metabolic reactions involving steroid hormones, and enzyme activity has been reported to be induced and/or inhibited in the presence of some sex steroids. Based on published studies for most CYP3A substrates, sex does not appear to influence clearance; however, with certain substrates significant sex-related differences are found. In such cases, women primarily have higher clearance than men.
引用
收藏
页码:33 / 60
页数:28
相关论文
共 50 条
  • [1] The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates
    Monette M. Cotreau
    Lisa L. von Moltke
    David J. Greenblatt
    Clinical Pharmacokinetics, 2005, 44 : 33 - 60
  • [2] Risperidone and cytochrome P450 3A
    deLeon, J
    Bork, J
    JOURNAL OF CLINICAL PSYCHIATRY, 1997, 58 (10) : 450 - 450
  • [3] Cytochrome P450 3A and their regulation
    Burk, O
    Wojnowski, L
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 (01) : 105 - 124
  • [4] Cytochrome P450 3A and their regulation
    Oliver Burk
    Leszek Wojnowski
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369 : 105 - 124
  • [5] Factors Affecting the Clinical Development of Cytochrome P450 3A Substrates
    Megan A. Gibbs
    Natilie A. Hosea
    Clinical Pharmacokinetics, 2003, 42 : 969 - 984
  • [6] Factors affecting the clinical development of cytochrome P450 3A substrates
    Gibbs, MA
    Hosea, NA
    CLINICAL PHARMACOKINETICS, 2003, 42 (11) : 969 - 984
  • [7] The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity
    Gorski, JC
    Vannaprasaht, S
    Hamman, MA
    Ambrosius, WT
    Bruce, MA
    Haehner-Daniels, B
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (03) : 275 - 287
  • [8] Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects
    Wang, Xiaodong
    Wang, Jing
    Arora, Sujata
    Hughes, Lorraine
    Christensen, Jennifer
    Lu, Sharon
    Zhang, Zhi-Yi
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (04): : 488 - 499
  • [9] Posttranscriptional elevation of cytochrome p450 3A expression
    Zangar, RC
    Hernandez, M
    Novak, RF
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 231 (01) : 203 - 205
  • [10] Cytochrome P450 3A - Ontogeny and drug disposition
    de Wildt, SN
    Kearns, GL
    Leeder, JS
    van den Anker, JN
    CLINICAL PHARMACOKINETICS, 1999, 37 (06) : 485 - 505